Due in part to its acquisition of Madison’s Exact Sciences, Abbott reported second quarter sales growth of 13% and raised its full-year 2026 earnings per share guidance range.
The results for the second quarter ended June 30 were announced Thursday morning during a conference call with investors.
Abbott reported overall sales of $12.6 billion, including $5.2 billion in U.S. sales, during the second quarter. For the year to date, sales grew to $23.8 billion, including $9.5 billion in the U.S.
Abbott raised its full-year 2026 adjusted earnings per share guidance range to $5.45 to $5.60, compared to the previous range of $5.38 to $5.58.
The company also reaffirmed its full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.
“Our second-quarter results reflect the momentum we are building,” Robert B. Ford, chairman and chief executive officer of Abbott, said in a statement. “We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”
Abbott completed its acquisition of Exact Sciences at the end of the first quarter. Full second quarter cancer diagnostics revenue totaled $919 million — $890 million in the U.S. and $29 million internationally.
Abbott said its second quarter cancer diagnostics results were driven by “mid-teens” growth of Cologuard, which was developed by Exact Sciences and is benefiting from a growing base of both new and repeat users.
Results in the quarter also reflect contributions to growth from the precision oncology and international businesses, the company said.
During the second quarter, the American Cancer Society issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard and Cologuard Plus as preferred screening options for adults age 45 and older who are at average risk for CRC.
